JOHNSON & JOHNSON is 495.6x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($574.10 B vs $1.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | XERS | JNJ |
|---|---|---|
| Market cap | $1.16 B | $574.10 B |
| US-listed rank | #2528 | #20 |
| Revenue (latest FY) | $291.85M | $94.19B |
| Net income (latest FY) | $554.00K | $26.80B |
| Net margin | 0.2% | 28.5% |
| P/E (trailing FY) | 2091.0 | 21.4 |
| SEC filings | 290 | 984 |
JOHNSON & JOHNSON is 495.6x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($574.10 B vs $1.16 B).
In their latest fiscal years, Xeris Biopharma Holdings, Inc. reported $291.85M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Xeris Biopharma Holdings, Inc. and JOHNSON & JOHNSON, or browse the full rankings.